

Company description/summary

InnoMedica's vision is to replace the systemic application of drugs with a targeted, and therefore gentler, approach by refining the most effective active ingredients into intelligent therapies using liposomal nanotechnology. The mission is therefore to enhance therapies for diseases with great therapeutic need, such as cancer, Parkinson's or ALS, or to make therapy possible in the first place, in order to achieve real medical progress for the people affected.

Company and Financials

- **Company:** InnoMedica Holding AG, fully owned subsidiaries, Switzerland/Germany
- **Financing:** a total of 10 public capital increases, 1,400 shareholders, CHF 65m raised
- **IPO:** SIX Swiss Exchange or Nasdaq in 2024 after breakeven, IFRS reporting since 2019
- **Cash burn:** CHF 0.9m per month
- **Cash at the end of 2022:** CHF 16.5m
- **Largest shareholder:** 18 percent
- **Shareholder pool:** a group of five entities with 42 percent shareholdings
- **Number of share classes:** one class of registered shares, nominal value CHF 0.10
- **Number of shares outstanding:** 14,339,550
- **Current pre-IPO financing round:** CHF 34.16m, closing in May 2023

Clinical Assets

- **Talineuren (TLN-1):** first-in-class clinical-stage Parkinson's disease treatment, weekly intravenous application of GM1-ganglioside in a blood-brain barrier crossing lipid nanoparticle, phase I/IIa study with significant reduction of MDS-UPDRS and no severe adverse events, a new mode of action with a strong data suggesting a disease-modifying effect on Parkinson's disease.
- **Talidox (TLD-1):** best-in-class clinical-stage breast cancer treatment, monthly intravenous application of doxorubicin in a lipid nanoparticle, currently under review for market approval by Swissmedic, highest AUC and serum half-life of more than 120 hours, largely reduced undesired drug reactions and 70 percent disease control rate.

Manufacturing, Technology, and IP

- **Manufacturing:** in-house manufacturing with a novel approach to lipid nanoparticle production, vertically integrated and fully GMP-compliant from procurement, raw material release, production, filling of final dosage form, quality control, quality assurance, cold-room storage, product release, and shipping. Advantage: in-house know-how built over 10 years of development time, active balancing of trade secrets versus patents, currently unaffected by supply-chain disruptions.
- **Technology:** newly developed lipid nanoparticle platform capable of efficient site-directed drug delivery, reaching unprecedented efficacy-toxicity profiles for existing and new molecular entities. The in-house manufacturing technology enables InnoMedica to produce a multiverse of highly functional lipid nanoparticles with the world's smallest diameter of 30 nanometers.
- **IP:** strong patent protection, latest patent: Liposomes comprising sphingomyelin WO2019122220A1 protecting the blood-brain barrier crossing capabilities of InnoMedica liposome technology (Notice of Allowance by USPTO in November 2022)